Summary of the Conference Call Company and Industry Overview - The conference call focused on **Lemon Bio** (莱芒生物科技有限公司), a clinical-stage immunometabolic innovative drug development company specializing in AI-enabled therapies, particularly in the field of CAR-T cell therapy. The company is co-founded by a team from the Swiss Federal Institute of Technology in Lausanne and is developing a unique platform called **Meta 10** for immune metabolic reprogramming. Key Points and Arguments AI-Enabled Drug Development - The integration of AI in innovative drug development is a significant focus for the industry, particularly in the context of the 2026 annual strategy, highlighting the importance of platform and model capabilities in valuation [1][2] - The effectiveness of AI-enabled platforms is measured by the efficiency and value of the projects they support, with promising data emerging from various clinical stages [2] Lemon Bio's Unique Technology - Lemon Bio has developed the world's first immune metabolic reprogramming technology platform based on interleukin-10 (IL-10), which addresses T-cell exhaustion, significantly improving the efficacy of existing immunotherapies [4] - The company’s metabolic-enhanced CAR-T products have shown remarkable results in clinical studies, including a 100% complete response rate in certain indications [4][5] Clinical Efficacy and Safety - The CAR-T therapy can be administered at a dosage reduced to 1/1000 of conventional CAR-T therapies, which is unprecedented in the industry, leading to lower production costs and shorter manufacturing cycles [5][10] - Clinical trials have demonstrated significant efficacy, with patients achieving complete remission and maintaining this state for over two years [6][18] Market Potential and Competitive Advantage - The market for CAR-T therapies is projected to be substantial, with Lemon Bio's products positioned to offer lower treatment costs and higher safety profiles compared to existing therapies [8][24] - The company has received multiple accolades for its innovative technology, including recognition at national innovation competitions and international clinical conferences [7][8] Future Directions and Research - Lemon Bio is exploring the application of its technology in treating solid tumors, with ongoing clinical trials aimed at addressing challenges such as immune suppression and T-cell exhaustion in the tumor microenvironment [12][30] - The company is also developing a fully automated, closed production system to enhance efficiency and reduce costs further [46] Intellectual Property and Innovation - Lemon Bio has secured multiple patents related to its core technologies and is continuously expanding its intellectual property portfolio to protect its innovations in CAR-T therapies and AI applications [37][38] Additional Important Content - The discussion included insights into the potential for the Meta 10 platform to be adapted for various modalities beyond CAR-T, including in vivo applications [24][39] - The company is leveraging AI to optimize drug design and clinical trial protocols, enhancing the overall efficiency of drug development processes [40][41] - The production cycle for the metabolic-enhanced CAR-T is currently around 2-3 weeks, but with new automated systems, this is expected to reduce to 5-7 days, significantly lowering costs [45][46] This summary encapsulates the key discussions and insights from the conference call, highlighting Lemon Bio's innovative approach to CAR-T therapy and its strategic positioning in the biotechnology industry.

消息面上，在创新治疗领域，中国企业的国际合作一直在持续。此前，百利天恒将双抗AD授权给百时 美施贵宝，以84亿美元的金额刷新了中国ADC新药"出海"的交易金额纪录。而刚实现"A+H"两地上市的 恒瑞医药近年来的BD更是进展迅速。截至目前，恒瑞医药已经实现14笔创新药License-out（对外授 权），其中近三年对外授权9笔，合作方包括默克、默沙东等国际巨头，涉及GLP-1、ADC等热门领 域。2024年中国创新药对License-out完成94笔，出海交易总金额高达519亿美元，同比增长26%。 大而全：创新药ETF（159992）跟踪创新药指数，该指数布局创新药产业链龙头企业，既汇聚全球CXO 龙头企业，又包含国内仿创药企龙头，有望同时受益于AI赋能创新药、国产创新药出海、针对高价创 新药的医保丙类目录出台等。 中信建投证券认为，创新药板块近年来展现出强劲的技术驱动发展势头，尤其在抗体偶联药物 （ADC）、双特异性抗体（双抗）以及小分子疗法等领域取得了显著进展。以2025年美国临床肿瘤学 会（ASCO）年会为例，中国创新药企在此次会议上提交了超过70项口头报告，其中Late Breaking Abstra ...

消息面上，5月20日，港股创新药企三生制药与海外辉瑞公司签订重大许可协议，授予辉瑞在全球（不 包括中国内地）独家开发、生产及商业化双抗的权利。根据协议，三生制药将获得12.5亿美元首付款， 并可能获得高达48亿美元的里程碑付款，以及双位数百分比的销售提成。这一交易再次刷新了国产创新 药出海首付款金额纪录。近期创新药行业利好不断。2025年第一季度，中国创新药license-out交易已有 41起，总金额达369.29亿美元，仅3个月已接近2023年全年水平。 相关产品：港股创新药ETF（159567）、创新药ETF（159992） 大而全：创新药ETF（159992）跟踪创新药指数，该指数布局创新药产业链龙头企业，既汇聚全球CXO 龙头企业，又包含国内仿创药企龙头，有望同时受益于AI赋能创新药、国产创新药出海、针对高价创 新药的医保丙类目录出台等。 国元证券认为，上周医药板块受特朗普宣布将推动美国处方药价格与"其他发达国家"对标政策影响，创 新药细分领域出现回调。特朗普提出行政令计划，旨在使美国药价下降30%-80%，并允许患者直接从制 造商购买药物，绕过中间商。然而，分析指出该政策实施难度较大，美国医药市场 ...

5月份开始，业绩真空期到来，市场关注点由业绩转变为行业与基本面，市场及行业主题的细分投资主线也更加 值得关注。当前，我国创新药进入成果兑现阶段，研发进展催化较多，且受到贸易战影响较小，或有较大的市场 发展潜力。 一、全球舞台彰显实力，ASCO数据印证国产创新药崛起 2025年美国临床肿瘤学会（ASCO）年会将于美国东部时间5月30日至6月3日在芝加哥以线上结合线下的形式拉开 帷幕。根据统计，今年口头汇报研究中共有73项为中国研究，各专场分布情况分别为：口头摘要专场为32项，摘 要速递专场为33项，临床科学研讨会为8项。就摘要重磅程度而言，广受关注的Late Breaking Abstract（LBA） 中，中国研究为11项。数量和占比相比往年都有明显提升。多家国产创新药企携针对不同病症的抗癌药参会，届 时多种兼具疗效与安全性的创新药有望逐步进入收获期。 图：2023-2025中国创新药报告对比，2025年数量和占比均提升 来源：中信建投 除了医药行业的政策利好，消费领域的重要政策也有望促进创新药领域发展。4月7日，商务部、国家卫生健康委 员会等12部门印发《促进健康消费专项行动方案》，提出了十项主要任务： （ ...

市场期待DeepSeek-R2大模型5月发布。年初DeepSeek爆火带动AI概念扩散至创新药。据了解，目前AI 算法在临床前药物发现阶段已经有深入应用，海外头部临床CRO公司在临床试验中已经布局AI多年， 完全由AI研发的新药有望在1～2年内成功上市。而且，AI可以赋能药物研发的全流程，相关的企业有 望通过AI技术缩短研发周期、降低成本、提高效率。 大而全：创新药ETF（159992）跟踪创新药指数，该指数布局创新药产业链龙头企业，既汇聚全球CXO 龙头企业，又包含国内仿创药企龙头，有望同时受益于AI赋能创新药、国产创新药出海、针对高价创 新药的医保丙类目录出台等。 信达证券认为，创新药板块在2025年第二季度展现出较高的投资价值，这主要得益于一系列积极的行业 动态和政策支持。首先，随着医保谈判、医保丙类目录落地预期以及多个重要肿瘤药临床会议等事件的 催化，创新药市场有望迎来新的增长点。其次，随着医疗整顿负面影响的逐步消化，院内市场的恢复将 为创新药的销售提供更稳定的环境。综上所述，创新药板块在多重利好因素的共同作用下，具备较高的 投资吸引力。 相关产品：港股创新药ETF（159567）、创新药ETF（15 ...

Group 1 - The core viewpoint is that the diversification of payment for innovative drugs is progressing, with a focus on establishing a comprehensive and multi-tiered commercial insurance drug catalog system in China [1] - The "full coverage" approach aims to expand the drug catalog to include all drugs approved by domestic and foreign regulatory agencies, with a draft proposal circulating for industry feedback [1] - The Hong Kong stock market saw a slight fluctuation on April 11, but the innovative drug sector experienced a counter-trend increase, with the innovative drug index's price-to-earnings ratio dropping from 64 times on February 21 to 24 times, indicating a significant improvement in value [1] Group 2 - The innovative drug ETF (159992) tracks an index that includes leading companies in the innovative drug industry, benefiting from trends such as AI-enabled drug development and the introduction of a new insurance catalog for high-priced innovative drugs [2] - The government has signaled strong support for the innovative drug sector, designating it as one of the top ten tasks in the 2025 government work report, which includes measures to enhance drug pricing mechanisms and support innovative drug development [2] - The government initiatives aim to create a more favorable environment for the innovative drug industry by promoting provincial-level coordination of basic medical insurance and reforming payment methods [2]